Correction: Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma

The Original Article was published on 05 July 2017

Nature 547, 217–221 (2017); doi:https://doi.org/10.1038/nature22991

In this Letter, the ‘Data availability’ section in the Methods should state ‘WES and RNA-seq data are deposited in dbGaP (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001451.v1.p1). All other data are available from the corresponding author upon reasonable request.’ instead of ‘All data are available from the corresponding author upon reasonable request’. In addition, the ‘Competing interests’ statement should include: ‘C.J.W. is subject to a conflict of interest management plan for the reported studies because of her competing financial interests in Neon Therapeutics. Under this plan, C.J.W. may not access identifiable human subjects’ data nor otherwise participate directly in the IRB-approved protocol reported herein. C.J.W.’s contributions to the overall program strategy and data analyses occurred on a de-identified basis.’ These errors have been corrected in the online versions of the Letter.

Authors

Additional information

The online version of the original article can be found at https://doi.org/10.1038/nature22991

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ott, P., Hu, Z., Keskin, D. et al. Correction: Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 555, 402 (2018). https://doi.org/10.1038/nature25145

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing